Beam Therapeutics Inc. (BEAM)


-0.91 (-2.65%)
Symbol BEAM
Price $33.45
Beta 1.627
Volume Avg. 0.93M
Market Cap 2.549B
Shares () -
52 Week Range 28.04-73.27
1y Target Est -
DCF Unlevered BEAM DCF ->
DCF Levered BEAM LDCF ->
ROE -37.58% Strong Sell
ROA -21.55% Sell
Operating Margin -
Debt / Equity 82.93% Buy
P/E -7.52 Strong Sell
P/B 3.23 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest BEAM news

Mr. John M. Evans M.B.A.
NASDAQ Global Select

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.